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Résumé en
anglais
Tumor-induced expansion of myeloid-derived suppressor cells (MDSCs) is known to
impair the efficacy of cancer immunotherapy. Among pharmacological approaches
for MDSC modulation, chemotherapy with selected drugs has a considerable interest
due to the possibility of a rapid translation to the clinic. However, such approach is
poorly selective and may be associated with dose-dependent toxicities. In the
present study, we showed that lipid nanocapsules (LNCs) loaded with a lauroyl-
modified form of gemcitabine (GemC12) efficiently target the monocytic MDSC
subset. Subcutaneous administration of GemC12-loaded LNCs reduced the
percentage of spleen and tumor-infiltrating M-MDSCs in lymphoma and melanoma-
bearing mice, with enhanced efficacy when compared to free gemcitabine.
Consistently, fluorochrome-labeled LNCs were preferentially uptaken by monocytic
cells rather than by other immune cells, in both tumor-bearing mice and human
blood samples from healthy donors and melanoma patients. Very low dose
administration of GemC12-loaded LNCs attenuated tumor-associated
immunosuppression and increased the efficacy of adoptive T cell therapy. Overall,
our results show that GemC12-LNCs have monocyte-targeting properties that can be
useful for immunomodulatory purposes, and unveil new possibilities for the
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